A Novel Fibrinogen Variant in a Chinese Pedigree with Congenital Dysfibrinogenemia Caused by FGA P. Arg38Thr Mutation: A Case Report

Overview

Journal Medicine (Baltimore)

Specialty General Medicine

Date 2018 Oct 7

PMID 30290666

Citations 1

Authors

Ruimin Cai

Yi Li

Wenyang Wang

Xue Gao

Meirong Liu

Youxiang Diao

Yi Tang

Qiang Feng

Affiliations

Soon will be listed here.

Abstract

Rationale: Congenital dysfibrinogenemia (CD) is characterized by altered functional properties of the fibrinogen; people who suffer from CD often have a low activity of fibrinogen and the mutation in the genomic DNA.

Patient Concerns: A 6-year-old child was examined with a low activity of fibrinogen measured by Von Clauss method and PT-derived method which indicated a normal level of fibrinogen; this abnormality was also detected in her mother. The genomic DNA of all the family members was extracted, and all exons of 3 fibrinogen genes which encode fibrinogen alpha chain (FGA), fibrinogen beta chain (FGB), and fibrinogen gamma chain (FGG) were amplified by polymerase chain reaction (PCR), in addition, sanger sequencing, homologous sequence alignment and bioinformatics software were performed for the further analysis.

Diagnoses: CD in this pedigree is associated with c.113G>C in the exon 2 of FGA which caused Arg38Thr mutation.

Outcomes: The child and her mother showed a low plasma concentration of fibrinogen measured by Von Clauss method, whereas a normal result measured by PT-derived method; finally, c.113G>C in the exon 2 of FGA was detected in the pedigree which caused Arg38Thr mutation and it is the first report on a pedigree with CD caused by AαArg38Thr.

Lessons: This case gives us the lesson that not all patients with CD showed typical symptoms and laboratory test results; the result of fibrinogen concentration and antigen which is tested by Von Clauss method and immunoturbidimetric assay is various according to the condition of each CD patient.

Citing Articles

Congenital dysfibrinogenemia misdiagnosed and inappropriately treated as acute fatty liver in pregnancy: A case report and review of literature.

Jia Y, Zhang X, Wu Y, Wang Q, Yang S World J Clin Cases. 2022; 10(35):12996-13005.

PMID: 36569010 PMC: 9782930. DOI: 10.12998/wjcc.v10.i35.12996.

References

Casini A, Blondon M, Lebreton A, Koegel J, Tintillier V, De Maistre E . Natural history of patients with congenital dysfibrinogenemia. Blood. 2014; 125(3):553-61. PMC: 4296015. DOI: 10.1182/blood-2014-06-582866. View

Castaman G, Ghiotto R, Tosetto A, Rodeghiero F . Bbeta 14 Arg --> Cys variant dysfibrinogen and its association with thrombosis. J Thromb Haemost. 2005; 3(2):409-10. DOI: 10.1111/j.1538-7836.2005.01139.x. View

Mosesson M, Siebenlist K, Meh D . The structure and biological features of fibrinogen and fibrin. Ann N Y Acad Sci. 2001; 936:11-30. DOI: 10.1111/j.1749-6632.2001.tb03491.x. View

Park R, Doh H, An S, Choi J, Chung K, Song K . A novel fibrinogen variant (fibrinogen Seoul II; AalphaGln328Pro) characterized by impaired fibrin alpha-chain cross-linking. Blood. 2006; 108(6):1919-24. DOI: 10.1182/blood-2005-11-007591. View

Wada Y, Niwa K, Maekawa H, ASAKURA S, Sugo T, Nakanishi M . A new type of congenital dysfibrinogen, fibrinogen Bremen, with an A alpha Gly-17 to Val substitution associated with hemorrhagic diathesis and delayed wound healing. Thromb Haemost. 1993; 70(3):397-403. View

Cunningham M, Brandt J, Laposata M, Olson J . Laboratory diagnosis of dysfibrinogenemia. Arch Pathol Lab Med. 2002; 126(4):499-505. DOI: 10.5858/2002-126-0499-LDOD. View

Niwa K, Yaginuma A, Nakanishi M, Wada Y, Sugo T, ASAKURA S . Fibrinogen Mitaka II: a hereditary dysfibrinogen with defective thrombin binding caused by an A alpha Glu-11 to Gly substitution. Blood. 1993; 82(12):3658-63. View

Hoffman M, Monroe 3rd D . A cell-based model of hemostasis. Thromb Haemost. 2001; 85(6):958-65. View

Roberts H, Stinchcombe T, Gabriel D . The dysfibrinogenaemias. Br J Haematol. 2001; 114(2):249-57. DOI: 10.1046/j.1365-2141.2001.02892.x. View

10.

Marchi R, Lundberg U, Grimbergen J, Koopman J, Torres A, De Bosch N . Fibrinogen Caracas V, an abnormal fibrinogen with an Aalpha 532 Ser-->Cys substitution associated with thrombosis. Thromb Haemost. 2000; 84(2):263-70. View

11.

Shapiro S, Phillips E, Manning R, Morse C, Murden S, Laffan M . Clinical phenotype, laboratory features and genotype of 35 patients with heritable dysfibrinogenaemia. Br J Haematol. 2012; 160(2):220-7. DOI: 10.1111/bjh.12085. View

12.

Bucciarelli P, Lammle B, Furlan M . Fibrinogen Milano XIII (Aalpha 19 Arg-->Gly): a dysfunctional variant with an amino acid substitution in the N-terminal polymerization site. Thromb Res. 1999; 96(5):399-405. DOI: 10.1016/s0049-3848(99)00128-0. View

13.

Mann K, Brummel K, Butenas S . What is all that thrombin for?. J Thromb Haemost. 2003; 1(7):1504-14. DOI: 10.1046/j.1538-7836.2003.00298.x. View

14.

Keinath K, Church T, Fogarty B, Sadowski B, Perkins J . Acute renal artery infarction secondary to dysfibrinogenemia. BMJ Case Rep. 2017; 2017. PMC: 5695362. DOI: 10.1136/bcr-2017-221375. View

15.

Shen Y, Trang V, Sarode R, Brennan S . Fibrinogen Dusart presenting as recurrent thromboses in the hepatic portal system. Blood Coagul Fibrinolysis. 2014; 25(4):392-4. DOI: 10.1097/MBC.0000000000000045. View

16.

Huang D, Chen H, Hu X, Wang X, Wang H . Identification of a novel splicing mutation in the fibrinogen gamma chain gene leading to dysfibrinogenaemia in a Chinese pedigree. Pathology. 2015; 47(2):145-50. DOI: 10.1097/PAT.0000000000000213. View

17.

Casini A, Neerman-Arbez M, Ariens R, de Moerloose P . Dysfibrinogenemia: from molecular anomalies to clinical manifestations and management. J Thromb Haemost. 2015; 13(6):909-19. DOI: 10.1111/jth.12916. View

18.

Neerman-Arbez M, Moerloose P, Casini A . Laboratory and Genetic Investigation of Mutations Accounting for Congenital Fibrinogen Disorders. Semin Thromb Hemost. 2016; 42(4):356-65. DOI: 10.1055/s-0036-1571340. View